BioRem's stock rose by 39% recently, with a focus on Return on Equity (ROE) to assess company performance. Despite a high ROE, the company's net income decreased, raising concerns about its growth potential.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing